HSBC analyst Yifeng Liu upgraded Moderna to Hold from Reduce with a price target of $69, down from $89. The firm says Moderna’s 2024 guidance of a minimum of $4B revenue was below its bearish expectation. However, the analyst believes the current share price adequately reflects the current outlook for Moderna. HSBC says the downside has played out.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRNA: